����VR��Ƶ

Statement from ����VR��Ƶ CEO, Dr Richard Hatchett, welcoming the

"At this worrying stage of the pandemic, it is hugely welcome news that the world now has a powerful new weapon in its arsenal of tools to fight COVID-19.

"Novavax's vaccine is the first protein-based COVID-19 vaccine to receive Emergency Use Listing — a prerequisite for distribution by COVAX - which means it is now poised to play a central role in COVAX's mission to protect those most at risk from the virus.

"NVX-CoV2373 is safe, effective against multiple variants, and can be stored in a regular refrigerator so it can be rolled out easily without costly and burdensome cold chain requirements.

"With over 1 billion doses accessible to COVAX, I expect this ����VR��Ƶ-supported vaccine to make a significant contribution to controlling the pandemic globally."


About ����VR��Ƶ's investments in NVX-CoV2373

����VR��Ƶ was one of the first investors in Novavax's COVID-19 vaccine candidate, NVX-CoV2373, and has to date provided up to US $399 million in funding to accelerate development and manufacturing of the vaccine for equitable global allocation.

In March 2020, ����VR��Ƶ provided up to US $4 million for Novavax to use their recombinant protein nanoparticle technology to develop a vaccine candidate against COVID-19.

����VR��Ƶ's second investment, in May 2020, provided up to US $384 million to support preclinical studies, Phase 1 and Phase 2 clinical trials. The additional funding also supported the transfer of NVX-CoV2373 technology to manufacturing partners in different geographical regions for large-scale production of the vaccine. These investments were directly linked to equitable access commitments which have been key to enabling access to the vaccine through COVAX.